Lantheus (LNTH)
(Delayed Data from NSDQ)
$105.55 USD
+1.52 (1.46%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $105.57 +0.02 (0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$105.55 USD
+1.52 (1.46%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $105.57 +0.02 (0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Lantheus Holdings (LNTH) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Lantheus Holdings (LNTH) closed the most recent trading day at $59.83, moving +0.25% from the previous trading session.
Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Encompass Health (EHC), Piedmont to Build Loganville Facility
by Zacks Equity Research
Encompass Health (EHC) partners with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to better serve the rehabilitative care needs of the state and solidify its footprint.
Lantheus Holdings (LNTH) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) concluded the recent trading session at $62.52, signifying a -0.11% move from its prior day's close.
Is Lantheus (LNTH) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts See a 44.13% Upside in Lantheus Holdings (LNTH): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 44.1% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See Lantheus Holdings (LNTH) as a Buy: Should You Invest?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Lantheus Holdings (LNTH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Lantheus' (LNTH) DEFINITY Approved by FDA for Pediatric Use
by Zacks Equity Research
Lantheus' (LNTH) receipt of the expanded indication for DEFINITY is likely to address unmet medical needs of pediatric patients.
Acadia Healthcare (ACHC) Q4 Earnings Beat on Strong Admissions
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q4 results gain on strong growth in revenue per patient day. It expects adjusted EPS of $3.40-$3.70 for 2024, the mid-point of which implies a 3.2% rise from the 2023 reported figure.
Boston Scientific Corporation (BSX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Lantheus' (LNTH) robust segmental revenues drive its fourth-quarter performance.
Lantheus Holdings (LNTH) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
New Strong Buy Stocks for February 23rd
by Zacks Equity Research
IRDM, JSAIY, CAH, LNTH and CENTA have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2024.
Lantheus Holdings (LNTH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Lantheus Holdings (LNTH) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Lantheus Holdings (LNTH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 18.24% and 1.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Lantheus Holdings (LNTH) Could Surge 58.6%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Should You Invest in Lantheus Holdings (LNTH) Based on Bullish Wall Street Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Lantheus Holdings (LNTH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) fourth-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Lantheus Holdings (LNTH) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Lantheus Holdings (LNTH) closed at $57.46, marking a -0.5% move from the previous day.
Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.